Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions

Sun Hyun Bae,1 Mi-Sook Kim,2 Won Il Jang,3 Chul Koo Cho,2 Hyung Jun Yoo,3 Kum Bae Kim,2 Chul Ju Han,2 Su Cheol Park,3 and Dong Han Lee4

1Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon; Departments of 2Radiation Oncology, 3Internal Medicine, and 4CyberKnife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

Received: 23 January 2015
Accepted: 9 April 2015

Address for Correspondence:
Mi-Sook Kim, MD
Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, 75 Nowon-1-ro, Nowon-gu, Seoul 139-706, Korea
Tel: +82.2-970-1264, Fax: +82.2-970-2412
E-mail: mskim@kcch.re.kr

Funding: This work was supported by the National Nuclear R&D program of the Ministry of Education, Science and Technology, Republic of Korea (1711022056), and also by the Soonchunhyang University Research Fund (20150001).

INTRODUCTION

Hepatic injury after external beam radiotherapy (EBRT) to the liver was first described in the early 1960s; its clinical symptoms comprised rapid weight gain, an increase in abdominal girth, hepatomegaly, occasionally ascites or jaundice, and an elevation of liver enzymes, particularly serum alkaline phosphatase (1). The underlying pathology was identified as veno-occlusive disease, and this has become a classic model of radiation-induced liver disease (RILD) (2). Notwithstanding these clinical and pathological studies on RILD, EBRT has played a limited role in the treatment of liver cancers due to technical barriers over the past 30 yr. With the introduction of 3-dimensional conformal radiotherapy (3D-CRT) in the 1990s, however, multiple beams that are not in the axial plane can spare adequate volumes of the normal liver, and the use of dose-volume histograms (DVHs) can quantify the dose delivered to the normal liver (3). These technological advances have expanded EBRT indications for liver cancers. RILD was subdivided into classic RILD and non-classic RILD, and hepatic toxicity after 3D-CRT has been fairly well established with these endpoints (4).

This study evaluated the incidence of hepatic toxicity after stereotactic ablative radiotherapy (SABR) using 3 fractions to the liver, and identified the predictors for hepatic toxicity. We retrospectively reviewed 78 patients with primary and metastatic liver cancers, who underwent SABR using 3 fractions between 2003 and 2011. To examine the incidence of hepatic toxicity, we defined newly developed hepatic toxicity ≥ grade 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 within 3 months after the end of SABR as a significant adverse event. To identify the predictors for hepatic toxicity, we analyzed several clinical and dosimetric parameters (\(V_{20Gy}-V_{35Gy}\): normal liver volume receiving < 20 Gy, reverse \(V_{50Gy}\)). Hepatic toxicity ≥ grade 2 occurred in 10 patients (13%); grade 2 in 9 patients and grade 3 in 1 patient. On univariate analysis, baseline Child-Pugh (CP) score (5 vs. 6-8), normal liver volume, and planning target volume were the significant clinical predictors. All dosimetric parameters were significant: \(V_{20Gy}\) was the most significant predictor. On multivariate analysis, baseline CP score (hazard ratio, 0.026; \(P = 0.001\)) was the only significant predictor. In conclusion, SABR using 3 fractions in primary and metastatic liver cancers produces low hepatic toxicity, especially in patients with a baseline CP score of 5. However, further studies are needed to minimize hepatic toxicity in patients with baseline CP scores ≥ 6.

Keywords: Child-Pugh Score; Liver Neoplasms; Hepatic Toxicity; Predictor; Stereotactic Body Radiotherapy

On the other hand, RILD rarely occurs after stereotactic ablative radiotherapy (SABR), which is a newly emerging treatment method to deliver a high dose to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body (5-7). Therefore, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) or the progression of Child-Pugh (CP) class have been used in evaluating hepatic toxicity after SABR. To date, a few studies have reported several predictors that affect hepatic toxicity after SABR using various fractionation schemes (8-14). Considering that the main obstacle for safe application of SABR remains the unavailability of data that allow the unambiguous determination of the parameters for fractionation schemes and dose prescriptions, however, additional studies should be needed to establish hepatic toxicity (15).

Therefore, this study included SABR in only 3 fractionations to avoid the ambiguity that arises while converting total doses from different fractions to the biologically equivalent dose. We evaluated the incidence of hepatic toxicity in primary and metastatic liver cancers after SABR using 3 fractions, and identified the predictors for hepatic toxicity.
MATERIALS AND METHODS

Patient selection
For patients with unresectable hepatocellular carcinoma (HCC), we conducted a SABR dose-escalation study with 33-57 Gy delivered in 3-4 fractions between 2003 and 2008, and a phase II SABR study with 60 Gy delivered in 3 fractions between 2008 and 2011 (16, 17). We registered 108 consecutive patients and treated them using SABR with curative-intent (18).

Among these, 86 patients received SABR using 3 fractions. During the same period, 73 patients with other primary liver cancers or liver metastases received curative-intent SABR in 3 fractions using a similar tumor dose, and normal tissue constraints based on previous prospective studies: cholangiocarcinoma (23 patients), gall bladder cancer (3 patients), other primary liver cancers (2 patients), and liver metastases (45 patients) (19, 20).

To evaluate hepatic toxicity after SABR, we retrospectively reviewed the medical records of these 159 patients. Patients who met the following criteria were excluded from this study: 1) intrahepatic disease progression and/or application of additional treatment within 3 months after the completion of SABR (51 patients), 2) 2 sessions of SABR within 3 months (3 patients), 3) absence of blood test results within 3 months (20 patients), 4) loss of follow up (6 patients), and 5) absence of planning data (1 patient). The remaining 78 patients, treated with SABR using 3 fractions between 2003 and 2011, were included in this study.

SABR technique
SABR was administered using CyberKnife (n = 50) or RapidArc (n = 28). The simulation data were entered into CyberKnife planning system (Accuray Inc., Sunnyvale, CA, USA) or Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA, USA). Gross tumor volume (GTV) was identified and contoured by using axial computed tomography (CT) images. GTV was considered equal to clinical target volume. Planning target volume (PTV) was defined as GTV plus 4 mm in the longitudinal direction and GTV plus 2 mm in all other directions. Radiation doses were prescribed at 74%-84% isodose line of the maximum dose for the CyberKnife and at 90%-100% for the RapidArc in order to cover at least 95% of the PTV. We adopted the liver dose constraints that at least 700 mL of the normal liver volume (total liver volume minus PTV) had to receive a total dose of < 15 Gy (phase I) or < 17 Gy (phase II) in HCC studies. The details of treatment have been described in our previous studies (16, 17).

Evaluation of hepatic toxicity
Before SABR, patients underwent physical examination, blood tests, and CT to assess baseline hepatic function and to evaluate the tumor extent. Every 1 to 3 months after the completion of SABR, patients underwent physical examination, blood tests, and CT to assess hepatic toxicity and to evaluate the tumor response. Hepatic toxicity was scored according to CTCAE v4.0 by analyzing the serum of aspartate transaminase, alanine transaminase, alkaline phosphatase, albumin, total bilirubin, and prothrombin time, and checking the presence of hepatic failure. We defined newly-developed hepatic toxicity ≥ grade 2 in the absence of documented progressive disease within 3 months after the end of SABR as significant adverse events.

Analysis of parameters and statistics
To determine the clinical predictors for hepatic toxicity ≥ grade 2, various clinical parameters such as age (< 60 vs. ≥ 60 yr), sex (male vs. female), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs. 2), origin (HCC vs. others), liver cirrhosis (yes vs. no), viral hepatitis (yes vs. no), baseline CP score (liver function before SABR, 5 vs. 6-8), SABR duration (3 vs. 4-10 days), PTV (≤ 47 vs. > 47 mL), and normal liver volume (< 1,000 vs. ≥ 1,000 mL) were analyzed as binary variables. To determine the dosimetric predictors for hepatic toxicity ≥ grade 2, we analyzed $V_{5Gy}$ (normal liver volume receiving < 5 Gy), $V_{10Gy}$, $V_{15Gy}$, $V_{20Gy}$, $V_{25Gy}$, $V_{30Gy}$, and $V_{35Gy}$ as continuous variables. These dosimetric parameters were calculated from DVHs.

Patients were grouped according to the severity of hepatic toxicity (grade 0-1 vs. grade 2-3). Univariate logistic regression analysis was used to compare the clinical and dosimetric parameters between the two groups. In addition, we used the Hosmer-Lemeshow test to predict for the goodness of fit for statistically significant dosimetric parameters from the logistic regression analysis. A low value of the test statistic, and a corresponding high $P$ value, indicated that there was good agreement between the observed and expected number of events. All significant clinical parameters and the most-predictive dosimetric parameter were evaluated by multivariate logistic regression analysis. All calculations were performed using the Statistical Package for the Social Sciences software version 13.0 (SPSS Inc., Chicago, IL, USA).

Ethics Statement
This study was approved by the Korea Institute of Radiological and Medical Sciences institutional review board (IRB No. K-1210-002-016). Our institutional review board waived the need for written informed consent for the participants because this study was retrospective in nature and did not infringe on the patients’ rights to data anonymity prior to analysis.

RESULTS

Patient characteristics
The 78 patients were comprised of 53 males (68%) and 25 females (32%), ranging in age from 33 to 79 yr (median, 60 yr). The ECOG performance status was 1 in 73 patients (94%) and 2 in 5 patients
Table 1. Characteristics of patients who experienced hepatic toxicity ≥ grade 2 within 3 months after the end of stereotactic ablative radiotherapy (SABR)

| No | Sex/Age | Primary | Normal liver volume (mL) | PTV (mL) | rV_{5 Gy} (mL) | rV_{20 Gy} (mL) | Hepatic Toxicity* | CP score | Clinical manifestations of hepatic toxicity |
|----|---------|---------|--------------------------|---------|----------------|----------------|-----------------|----------|------------------------------------------|
| 1  | M/50    | HCC     | 1,191                    | 42      | 1,051          | 1025           | 1               | 2        | 5 6 Hyperbilirubinemia                   |
| 2  | M/70    | CC      | 741                      | 209     | 397            | 321            | 1               | 2        | 5 6 ALP increased                      |
| 3  | M/59    | HCC     | 1,109                    | 34      | 1,004          | 985            | 1               | 2        | 6 6 Hyperbilirubinemia                 |
| 4  | M/49    | HCC     | 1,167                    | 118     | 986            | 607            | 0               | 2        | 6 7 Hypoalbuminemia, Asciites           |
| 5  | M/73    | HCC     | 914                      | 65      | 757            | 731            | 1               | 2        | 6 8 Hypoalbuminemia, Asciites           |
| 6  | F/62    | HCC     | 889                      | 38      | 766            | 729            | 1               | 3        | 6 10 Hyperbilirubinemia, Hepatic encephalopathy† |
| 7  | M/61    | HCC     | 842                      | 188     | 700            | 677            | 1               | 2        | 6 8 Hypoalbuminemia, Ascites            |
| 8  | F/69    | HCC     | 717                      | 62      | 590            | 556            | 0               | 2        | 6 7 Hyperbilirubinemia                 |
| 9  | F/66    | HCC     | 1,104                    | 86      | 880            | 838            | 1               | 2        | 7 8 Hyperbilirubinemia                 |
| 10 | F/67    | HCC     | 724                      | 18      | 626            | 594            | 1               | 2        | 7 8 Hyperbilirubinemia                 |

*Was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0; †was accompanied with diarrhea at 2 weeks after the end of SABR. HCC, hepatocellular carcinoma; CC, cholangiocarcinoma; Normal liver volume, total liver volume minus planning target volume (PTV); CP score, Child-Pugh score; ALP, alkaline phosphatase; rV_{xGy}, normal liver volume receiving < x Gy, reverse V_{xGy}.

Hepatic toxicity ≥ grade 2
The characteristics of patients, who experienced hepatic toxicity ≥ grade 2 within 3 months after the end of SABR, are shown in Table 1. Ten patients (13%) experienced hepatic toxicity ≥ grade 2. The clinical manifestations of hepatic toxicity were hyperbilirubinemia, elevation of hepatic enzyme, hypoalbuminemia, ascites, and hepatic encephalopathy. Among these, 5 patients (6%) experienced the progression of CP class: from A to B in 4 patients; from A to C in 1 patient. Three patients with hypoalbuminemia of grade 2 were always accompanied with ascites of grade 2, which induced the progression of CP class. On the contrary, among the 5 patients with hyperbilirubinemia of grade 2, only 1 patient experienced the progression of CP class.

Predictors for hepatic toxicity
The results of the univariate analysis for clinical and dosimetric predictors affecting hepatic toxicity ≥ grade 2 are summarized in Table 2 and Table 3. The baseline CP score, PTV, and normal liver volume were statistically significant clinical predictors. And all dose-volumetric parameters of rV_{5 Gy}-rV_{20 Gy} were statistically significant. The result of the Hosmer-Lemeshow test was not statistically significant (P = 0.768), suggesting a good calibration of the models using these dose-volumetric parameters: among these, rV_{20 Gy} was the most significant predictor (P = 0.013). On multivariate logistic regression analysis containing all significant clinical predictors according to univariate analysis and the most-predictive dosimetric parameter (rV_{20 Gy}), the baseline CP score (5 vs. 6-8) was the only significant predictor for hepatic toxicity ≥ grade 2 (hazard ratio, 0.026; 95% confidence interval, 0.003-0.221, P = 0.001). Fig. 1 shows DVHs of the normal liver from all patients. Patients with a CP score of 5 were tolerable although a larger volume of the normal liver was irradiated.

DISCUSSION
Hepatic toxicity is one of the most important toxicities when EBRT is applied to the liver. Historically, hepatic toxicity after conventional RT has been well documented as RILD. RILD typically occurred between 2 weeks to 3 months after conventional RT and the overall incidence of RILD was 7%-20% (4, 21). However, RILD rarely occurred with ≤ 5% of cases after SABR (4, 6). In our study, RILD was found to occur in 1% of patients. In contrast to conventional RT, the low rate of RILD after SABR can be ascribed to three main reasons. First, there is a substantial difference in normal liver dose distribution. SABR has a lower mean dose and minimizes the delivered dose to larger volumes of the normal liver by maintaining steep dose gradients, while conventional RT includes large volumes of the normal liver even in high-dose regions (6, 22). Second, high dose per fraction during...
SABR can induce endothelial damage, and consequently, reduced perfusion (23). This can result in diminished reoxygenation effects, unlike conventional RT, and affect different repair mechanisms on normal tissue (24). Finally, protracted dose delivery from SABR using gating method or intensity-modulated radiotherapy might allow the DNA repair processes to initiate before the entire RT dose is applied, increase survival especially in cells with a high repair capacity such as normal tissue, and decrease normal tissue toxicity (25). Therefore, SABR studies generally reported hepatic toxicity with other endpoints such as CTCAE criteria or the progression of CP class. Table 4 and Table 5 present the hepatic toxicity by these endpoints from prospective or retrospective studies using SABR for primary and metastatic liver cancers (8-14, 26-29). The overall incidence of hepatic toxicity was varied from 0% to 33%; our study reported an incidence of 13% for hepatic toxicity ≥ grade 2 and 6% for the progression of CP class. Prospective studies, in which patients had good baseline liver function and where a definite liver dose constraint (rV_{17Gy} ≥ 700 mL: generally recommended liver dose constraint) was met in all patients, reported no hepatic toxicity as shown in Table 4. On the other hand, Table 5 shows that hepatic toxicity occurred when definite liver dose constraints could not be strictly satisfied, regardless of the type of constraint. In the current study, the constraint of rV_{17Gy} of 13 patients was below 700 mL: 4 patients (31%) experienced hepatic toxicity ≥ grade 2.

Table 2. Univariate analysis for clinical predictors affecting hepatic toxicity ≥ grade 2 after stereotactic ablative radiotherapy (SABR)

| Parameters          | No. of patients | Without hepatic toxicity | With hepatic toxicity | P value |
|---------------------|-----------------|--------------------------|-----------------------|---------|
| Age (yr)            |                 |                          |                       |         |
| < 60                | 32              | 3                        |                       | 0.319   |
| ≥ 60                | 36              | 7                        |                       |         |
| Sex                 |                 |                          |                       |         |
| Male                | 47              | 6                        |                       | 0.566   |
| Female              | 21              | 4                        |                       |         |
| ECOG                |                 |                          |                       |         |
| 1                   | 65              | 8                        |                       | 0.087   |
| 2                   | 3               | 2                        |                       |         |
| Origin              |                 |                          |                       |         |
| HCC                 | 52              | 9                        |                       | 0.351   |
| Others*             | 16              | 1                        |                       |         |
| Liver cirrhosis     |                 |                          |                       | 0.142   |
| No                  | 24              | 1                        |                       |         |
| Yes                 | 44              | 9                        |                       |         |
| Viral hepatitis     |                 |                          |                       | 0.772   |
| No                  | 24              | 4                        |                       |         |
| Yes                 | 44              | 6                        |                       |         |
| Baseline CP score†  |                 |                          |                       | 0.000   |
| 5                   | 60              | 2                        |                       |         |
| 6/7/8               | 4/2/2          | 6/2/0                    |                       |         |
| SABR duration       |                 |                          |                       | 0.806   |
| ≤ 4 days           | 38              | 6                        |                       |         |
| > 4 days           | 30              | 4                        |                       |         |
| PTV (mL)            |                 |                          |                       | 0.042   |
| ≤ 47                | 43              | 2                        |                       |         |
| > 47                | 25              | 8                        |                       |         |
| Normal liver volume (mL) |         |                          |                       | 0.019   |
| < 1,000            | 15              | 6                        |                       |         |
| ≥ 1,000            | 53              | 4                        |                       |         |

*Includes liver metastases, cholangiocarcinoma, gallbladder cancer, and neuroendocrine carcinoma of liver; †Means Child-Pugh score before SABR. ECOG, Eastern Cooperative Oncology Group performance status; PTV, planning target volume; Normal liver volume, total liver volume minus PTV.

Table 3. Univariate analysis for dosimetric predictors affecting hepatic toxicity ≥ grade 2 after stereotactic ablative radiotherapy

| Radiation dose | Without hepatic toxicity | With hepatic toxicity | P value |
|---------------|--------------------------|-----------------------|---------|
| rV_{5Gy}      | 615.4 ± 317.7            | 401.4 ± 236.0         | 0.050   |
| rV_{10Gy}     | 825.1 ± 312.8            | 582.4 ± 224.6         | 0.027   |
| rV_{15Gy}     | 948.8 ± 292.3            | 692.1 ± 214.4         | 0.015   |
| rV_{17Gy}     | 985.3 ± 284.1            | 726.3 ± 207.7         | 0.013   |
| rV_{20Gy}     | 1,026.8 ± 276.1          | 763.7 ± 197.8         | 0.010   |
| rV_{25Gy}     | 1,073.6 ± 268.6          | 818.1 ± 192.4         | 0.009   |
| rV_{30Gy}     | 1,106.4 ± 264.2          | 852.3 ± 183.0         | 0.008   |
| rV_{35Gy}     | 1,131.6 ± 260.7          | 882.5 ± 180.2         | 0.008   |

*rV, normal liver volume receiving < X Gy, reverse Vx; SD, standard deviation.

Fig. 1. Dose-volume histograms (DVHs) of the normal liver (total liver volume minus planning target volume) from all patients. Grey color indicates patients with a CP score of 5; blue color with a CP score of 6; green color with a CP score of 7; red color with a CP score of 8. Solid lines represent patients without hepatic toxicity; dotted line with hepatic toxicity ≥ grade 2.
Table 4. Hepatic toxicity from prospective studies using stereotactic ablative radiotherapy for primary and metastatic liver cancers, which had a good baseline liver function and satisfied their own liver dose constraints in all patients

| Study design/Author | Origin (No. of pts) | CP class | Median dose (range, Gy)/ fx’s | Liver dose constraints | Incidence of hepatic toxicity |
|---------------------|---------------------|----------|-----------------------------|-----------------------|-----------------------------|
| Phase I Schefter (26) | HCC (2) | *| 51(36-60)/3 | rV_{15 Gy} ≥ 700 mL | No |
| Liver mets (16) | | | | | |
| Phase VIII Kavanagh (27) | Liver mets (36) | 2 | 60 (36-60)/3 | rV_{15 Gy} ≥ 700 mL | No |
| Phase VIII Rusthoven (28) | Liver mets (47) | *| 60 (36-60)/3 | rV_{15 Gy} ≥ 700 mL | No |
| Phase I Rule (29) | Liver mets (27) | A | 50 (30,50,60)/5-5 | rV_{15 Gy} ≥ 700 mL in 3 fx’s | No |

Table 5. Hepatic toxicity from prospective or retrospective studies using stereotactic ablative radiotherapy for primary and metastatic liver cancers, which had patients with a Child-Pugh (CP) class of B and did not strictly satisfy their own liver dose constraints in all patients

| Study design/Author | Origin (No. of pts) | CP class | Median dose (range, Gy)/ fx’s | Liver dose constraints | Incidence of hepatic toxicity | Predictor for hepatic toxicity |
|---------------------|---------------------|----------|-----------------------------|-----------------------|-----------------------------|-------------------------------|
| Phase I Cardenes (8) | HCC (17) | A, B | 36-48/3 in CP-A | rV_{15 Gy} ≥ 700 mL | V_{15 Gy} < 50% | |
| 40/5 in CP-B | | | | | Grade ≥ 2: 33% | CP class progression: 11% |
| Retrospective Son (9) | HCC (36) | A, B, C | 36 (30-39)/3 | V_{15 Gy} ≥ 700 mL | > Grade ≥ 2 | v \text{ for ≥ grade 2} |
| | | | | CP score | CP class progression: 11% | |
| Phase II Andolino (10) | HCC (60) | A, B | 44 (30-48)/3 in CP-A | V_{15 Gy} ≥ 700 mL | ≥ Grade ≥ 2 | V \text{ for ≥ grade 2} |
| 40 (24-48)/5 in CP-B | | | CP-A: D_{15 Gy} ≥ 10 Gy +V_{15 Gy} ≥ 500 mL | CP-B: D_{15 Gy} ≥ 18 Gy +V_{15 Gy} ≥ 500 mL | CP score for toxicity ≥ 1 grade | |
| Retrospective Billaud (11) | HCC (75) | A, B | 45 (24-45)/3 | V_{15 Gy} ≥ 700 mL | V_{15 Gy} < 50% | Ascites: 7% |
| Normal liver volume | | | +V_{15 Gy} < 33% | | | |
| Retrospective Jung (12) | HCC (92) | A, B | 45 (30-60)/3-4 | NS | ≥ Grade ≥ 2 | 19% |
| | | | | | CP class | |
| Retrospective Janoray (13) | HCC (21) | A, B | 45 or 60/3 | V_{15 Gy} ≥ 700 mL | +V_{15 Gy} ≥ 700 mL | CP score ≥ 35 mm for grade 3 |
| Liver mets (35) | | | | | +V_{15 Gy} < 33% | |
| CP class progression: 4% | | | | | | |
| | | | | | | |
| Retrospective Sanuki (14) | HCC (180) | A, B | 45/40 in CP-A | V_{15 Gy} < 20% | Grade ≥ 5 | 4% |
| 35/5 in CP-B | | | CP score > 2 points: 11% | | | |
| Current study | HCC (61) | A, B | 54 (36-60)/3 | V_{15 Gy} ≥ 700 mL | ≥ Grade ≥ 2 | 2% |
| Others* (17) | | | CP class progression: 6% | | | |
| Current study | | | | CP score for ≥ 2 grade | | |

*Includes liver metastases, cholangiocarcinoma, gallbladder cancer, and neuroendocrine carcinoma of liver. HCC, hepatocellular carcinoma; Liver mets, liver metastases; rV_{15 Gy}, normal liver volume receiving < X Gy, reverse V_{15 Gy}. RILD, radiation-induced liver disease.

ty ≥ grade 2; and 2 patients (15%) experienced the progression of CP class. Therefore we should set a definite liver dose constraint and should conduct SABR to the liver under a well-organized clinical setting, even though the optimal liver dose constraint remains unknown because of the small number of patients and heterogeneity in origin, tumor sizes, baseline liver functions, and the number of fractions. In cases where the liver dose constraint is not met, dose per fraction would be reduced or the number of fractions would be increased. This might mean the conversion from SABR into hypofractionation or conventional fractionations considering that sequential phase I and II trials of SABR for HCC patients with a baseline CP class of A, in which they used 6 fractions and prescribed relatively lower total doses (median 36 Gy), reported a 29% decline of CP class at 3 months after SABR (30).

Table 5 also shows the several predictors for hepatic toxicity after SABR. Several clinical and dosimetric predictors were involved in the development of hepatic toxicity. Among these studies, 5 studies including our study indicated that the baseline CP score was the most important predictor: 3 studies suggested that baseline CP scores ≥ 8 is not safe for SABR (8, 10, 14). A recent study which conducted SABR for HCC patients with CP class of B or C reported the highest incidence of hepatic toxicity 63% at 3 months after end of SABR (31). They found that treatment of patients with a CP class of B was not without risk of toxicity and suggested SABR as a treatment option for selected HCC patients with modestly impaired liver function (a baseline CP score of 7). On the other hand, our study showed that 2 patients with a baseline CP score of 8 did not experience hepatic toxicity ≥ grade 2. Although these patients had normal liver volumes of 754 mL and 634 mL due to underlying liver cirrhosis related to HBV, they had small PTVs (11 mL and 10 mL) and...
SABR plan was conducted to minimize the irradiation dose to the normal liver: \( rV_{15Gy} \) was 724 mL and 588 mL. Fig. 1 shows that these 2 patients received the lowest irradiation doses to the normal liver. Thus, SABR may be conditionally employed in patients with a baseline CP score of 8, only if the irradiation dose to the normal liver can be minimized. Otherwise, an increase of the number of fractions should be considered. In patients with a baseline CP score of 5, SABR to the liver would be considered as a safe treatment method. Among the 62 patients with a baseline CP score of 5 in this study, only 2 patients (3%) experienced hepatic toxicity of grade 2, without the progression of CP class. Fig. 1 represents patients with a baseline CP score of 5 who were tolerable in irradiation of higher doses to the normal liver than patients with baseline CP scores of 6-7. Therefore, SABR to the liver is a safe treatment option for patients with a baseline CP score of 5 based on the current liver dose constraint; however, further studies are needed to establish optimal liver dose constraint to minimize hepatic toxicity for patients with baseline CP scores of 6-7.

There were some limitations in the current study. First, this study was a retrospective analysis. Therefore, selection bias may have occurred, and the rate of hepatic toxicity may have been underestimated. Second, low incidence of hepatic toxicity was included although this study is one of having the largest number of patients and a fixed regimen of 3 fractions among the published studies focused on SABR. Therefore, we conducted statistical analysis with an endpoint of hepatic toxicity \( \geq \) grade 2. However, hepatic toxicity \( \geq \) grade 2 would not generally lead to severe radiation-induced morbidity or mortality in the long term (9). In our study, most patients with hepatic toxicity \( \geq \) grade 2 did not experience further deterioration in hepatic function. Considering that many studies for SABR to the liver did not report an evaluable number of patients at follow-up and accurate ratios of patients with hepatic toxicity, our study using CTCAE criteria with consistency of reporting is meaningful.

In conclusion, SABR using 3 fractions to primary and metastatic liver cancers produces acceptably low hepatic toxicity. On multivariate analysis, the baseline CP score (5 vs. 6-8) is the only significant predictor. Further studies should establish optimal liver dose constraint to minimize hepatic toxicity, especially in patients with baseline CP scores \( \geq \) 6.

**DISCLOSURE**

The authors have no conflicts of interest to disclose.

**AUTHOR CONTRIBUTION**

Conception and design of the study: Kim MS. Interpretation of data, statistical analysis, and manuscript preparation: Bae SH. Acquisition and interpretation of clinical data: Jang WI. Acquisition and interpretation of dosimetric data: Kim KB, Lee DH. Interpretation of data and revision of the manuscript: Cho CK, Yoo HJ, Han CJ, Park SC. Manuscript approval: all authors.

**REFERENCES**

1. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation Hepatitis. Am J Roentgenol Radiat Ther Nucl Med 1965; 93: 200-8.
2. Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48: 597-611.
3. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31: 1237-48.
4. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Mitlen M, Ten Haken RK. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76: S94-100.
5. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA, et al.; American Society for Therapeutic Radiology and Oncology; American College of Radiology. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004; 60: 1026-32.
6. Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011; 21: 256-63.
7. Loo BW Jr, Chang JY, Dawson LA, Kavanagh BD, Koong AC, Senan S, Timmerman RD. Stereotactic ablative radiotherapy: what’s in a name? Pract Radiat Oncol 2011; 1: 38-9.
8. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Scheufer TE, Tatum K, Deluca J, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010; 12: 218-25.
9. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010; 78: 1073-80.
10. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e447-53.
11. Bilbault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacormerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One 2013; 8: e77472.
12. Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, Song SY, Lee SW, Ahn SD, Choi EK, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 2013; 8: 249.
13. Janoray G, Chapet S, Ruffier-Loubière A, Bernadou G, Piontreau Y, Callais G. Robotic stereotactic body radiation therapy for tumors of the liver:
radiation-induced liver disease, incidence and predictive factors. Cancer Radiother 2014; 18: 191-7.

14. Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, Kimieda E. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 2015; 45: 540-7.

15. Papiez L, Timmerman R. Hypofractionation in radiation therapy and its impact. Med Phys 2008; 35: 112-8.

16. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010; 102: 209-14.

17. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung da H, Kim KB, Lee DH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118: 5424-31.

18. Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013; 8: 250.

19. Kim MS, Kang JK, Cho CK, Choi CW, Seo YS, Hwang DY, Moon SM, Kang HJ, Kim YH, Kim MS, et al. Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer. Tumori 2009; 95: 449-54.

20. Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, Yoo HJ, Seo YS, Lee DH, Kang HJ, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis 2010; 27: 273-8.

21. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53: 810-21.

22. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 2014; 32: 2847-54.

23. Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014; 190: 872-81.

24. Brown JM, Koong AC. High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys 2008; 71: 324-5.

25. Sterzing F, Münfer MD, Schäfer M, Haering P, Thilmann C, Debus J. Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 2005; 181: 42-8.

26. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005; 62: 1371-8.

27. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006; 45: 848-55.

28. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-8.

29. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer I, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011; 18: 1081-7.

30. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631-9.

31. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, Ringash J, Dawson LA. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111: 412-7.